Zura Bio director granted 51,000 stock options

Zura Bio Ltd director Amit Munshi received an option grant for 51,000 shares of Class A Ordinary Shares.

Accepted by SEC EDGAR 06/22/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Zura Bio Ltd director Amit Munshi received an option grant for 51,000 shares of Class A Ordinary Shares. The option has an exercise price of $3.62 per share and expires on June 17, 2036. It vests in twelve substantially equal monthly installments over one year starting June 17, 2026, with any remaining unvested portion vesting immediately before the next annual shareholder meeting, contingent on continued service.

Insider Trade Summary

Grant/Award: 51,000 shares

Grant/Award 1 txn

Insider Munshi Amit

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	51,000	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 51,000 contracts (Direct)

Footnotes (1)

1. F1. This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

Key Figures

Option grant size: 51,000 options Exercise price: $3.62 per share Expiration date: June 17, 2036 +2 more

5 metrics

Option grant size 51,000 options Grant of Share Option (Right to Buy) for Class A Ordinary Shares

Exercise price $3.62 per share Conversion or exercise price of the granted options

Expiration date June 17, 2036 Option expiration for the 51,000-share grant

Post-grant option holdings 51,000 options Total shares underlying options following this transaction

Vesting start June 17, 2026 Monthly vesting over one year from this date

Key Terms

Share Option (Right to Buy), Class A Ordinary Shares, vests in twelve substantially equal monthly installments, annual meeting of shareholders, +1 more

5 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

Class A Ordinary Shares financial

"underlying_security_title: "Class A Ordinary Shares""

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

vests in twelve substantially equal monthly installments financial

"This option vests in twelve substantially equal monthly installments over a one-year period"

annual meeting of shareholders financial

"will vest as of the day immediately preceding the next annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

exercise price financial

"conversion_or_exercise_price: "3.6200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Zura Bio (ZURA) director Amit Munshi report in this Form 4?

Amit Munshi reported receiving a stock option grant for 51,000 shares. The option is a right to buy Class A Ordinary Shares at a fixed exercise price and reflects equity-based compensation rather than an open-market stock purchase or sale.

What are the key terms of Amit Munshi’s 51,000-share option grant at Zura Bio (ZURA)?

The grant covers 51,000 shares with an exercise price of $3.62 per share and expires June 17, 2036. These options give Munshi the right, but not obligation, to buy Zura Bio Class A Ordinary Shares at that price before expiration.

How does the new Zura Bio (ZURA) option grant vest for Amit Munshi?

The option vests in twelve substantially equal monthly installments over one year starting June 17, 2026. Any remaining unvested portion vests immediately before the next annual shareholder meeting, provided Munshi continues to serve through each applicable vesting date.

Is Amit Munshi’s Form 4 transaction in Zura Bio (ZURA) a stock purchase or sale?

The Form 4 reports an acquisition of derivative securities through a grant, coded “A” for award. It is not an open-market purchase or sale; it reflects a compensation-related stock option award rather than trading in existing Zura Bio shares.

How many Zura Bio (ZURA) options does Amit Munshi hold after this grant?

After this reported transaction, Munshi holds 51,000 stock options from this grant. These options relate to 51,000 underlying Class A Ordinary Shares and represent the position shown for this award in the filing following the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Munshi Amit

(Last) (First) (Middle)

C/O ZURA BIO LTD

1489 W. WARM SPRINGS RD. #110

(Street)

HENDERSON NEVADA 89014

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$3.62	06/17/2026		A		51,000		(1)	06/17/2036	Class A Ordinary Shares	51,000	$0	51,000	D

Explanation of Responses:

1. This option vests in twelve substantially equal monthly installments over a one-year period measured from June 17, 2026; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.

	/s/ Kim Davis, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)